Sign InBreakout Stocks of Week 30 @ FRA
NASDAQ was down last week (week 29) by -2.90% ending at 25,520.24 points after falling -761.36 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are Ishares Dow Jones Global Titans 50 Ucits Etf (de) FRA:EXI2. This stock has had a buy signal since Jul 09, 2026 when the price was 110.74€ , but have so far fallen -0.452% to 110.24€. Some other companies are on our watchlist to, among these are Vanguard Eur Eurozone Government Bond Ucits Etf FRA:VGEA Scout24 AG FRA:G24 and Bechtle AG FRA:BC8 which all got a breakout pattern emerging.
| Date | Company | Price | Week 30 |
|---|---|---|---|
| Ishares Dow Jones Global Titans 50 Ucits Etf (de) | 110.24€ | 109.54€ | -0.635% |
| Vanguard Eur Eurozone Government Bond Ucits Etf | 23.89€ | 23.84€ | -0.205% |
| Scout24 Ag | 72.35€ | 68.40€ | -5.46% |
| Bechtle Ag | 30.28€ | 31.64€ | 4.49% |
The Ishares Dow Jones Global Titans 50 Ucits ETF price fell by -1.69% on the last day (Friday, 17th Jul 2026) from 112.14€ to 110.24€. During the last trading day the ETF fluctuated 0.749% from a day low at 109.50€ to a day high of 110.32€. The price has risen in 6 of the last 10 days but is still down by -0.09% for this period. Volume has increased on the last day by 18 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 27 thousand shares were bought and sold for approximately 2.99€ million.
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Ishares Dow Jones Global Titans 50 Ucits ETF to perform well in the short-term.
The Vanguard Eur Eurozone Government Bond ETF price gained 0.0293% on the last trading day (Friday, 17th Jul 2026), rising from 23.89€ to 23.89€. During the last trading day the ETF fluctuated 0.289% from a day low at 23.87€ to a day high of 23.94€. The price has fallen in 6 of the last 10 days and is down by -1.11% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 76 thousand more shares were traded than the day before. In total, 120 thousand shares were bought and sold for approximately 2.88€ million.
Several of the signals/indicators are negative, and we believe that this will affect on the development for the next days and maybe possible weeks. However, over time, we think that today's level holds a possible buying opportunity and that the price will be higher during or at the end of this 3-month period.
The Scout24 AG stock price fell by -2.36% on the last day (Friday, 17th Jul 2026) from 74.10€ to 72.35€. During the last trading day the stock fluctuated 2.99% from a day low at 71.90€ to a day high of 74.05€. The price has been going up and down for this period, and there has been a -0.89% loss for the last 2 weeks. Volume has increased on the last day by 92 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 249 thousand shares were bought and sold for approximately 17.98€ million.
Scout24 AG holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Scout24 AG:
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
The Bechtle AG stock price gained 0.331% on the last trading day (Friday, 17th Jul 2026), rising from 30.18€ to 30.28€. During the last trading day the stock fluctuated 1.67% from a day low at 29.92€ to a day high of 30.42€. The price has been going up and down for this period, and there has been a -4.24% loss for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 20 thousand more shares were traded than the day before. In total, 140 thousand shares were bought and sold for approximately 4.25€ million.
The Bechtle AG stock holds several negative signals and despite the positive trend, we believe Bechtle AG will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.
About Bechtle AG:
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
GOLDEN STAR
| Ticker | Change | Signal Date |
|---|---|---|
FOX
$50.81
|
2.22% | Jul 27 |
UNFI
$49.05
|
3.63% | Jul 27 |
BIIB
$202.19
|
0.376% | Jul 24 |
TSCO
$30.32
|
1.48% | Jul 23 |
|
S
SW
$43.71
|
5.17% | Jul 23 |
